Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets

• Main Authors: Paula I. Moreira, Gemma Casadesus, Mark A. Smith, George Perry, Hyoung-Gon Lee, Cristina Carvalho, Xiongwei Zhu, Sonia Correia, Susana Cardoso, Renato Santos
• Format: Article
• Language: English
• Published: MDPI AG 2009-12-01
• Series: Pharmaceuticals
• Subjects: Alzheimer’s disease; amyotrophic lateral sclerosis; Huntington’s disease; insulin; mitochondria; neurodegeneration; Parkinson’s disease; PPARs agonists
• Online Access: http://www.mdpi.com/1424-8247/2/3/250/

Insulin, besides its glucose lowering effects, is involved in the modulation of lifespan, aging and memory and learning processes. As the population ages, neurodegenerative disorders become epidemic and a connection between insulin signaling dysregulation, cognitive decline and dementia has been established. Mitochondria are intracellular organelles that despite playing a critical role in cellular metabolism are also one of the major sources of reactive oxygen species. Mitochondrial dysfunction, oxidative stress and neuroinflammation, hallmarks of neurodegeneration, can result from impaired insulin signaling. Insulin-sensitizing drugs such as the thiazolidinediones are a new class of synthetic compounds that potentiate insulin action in the target tissues and act as specific agonists of the peroxisome proliferator-activated receptor gamma (PPAR-γ). Recently, several PPAR agonists have been proposed as novel and possible therapeutic agents for neurodegenerative disorders. Indeed, the literature shows that these agents are able to protect against mitochondrial dysfunction, oxidative damage, inflammation and apoptosis. This review discusses the role of mitochondria and insulin signaling in normal brain function and in neurodegeneration. Furthermore, the potential protective role of insulin and insulin sensitizers in Alzheimer´s, Parkinson´s and Huntington´s diseases and amyotrophic lateral sclerosis will be also discussed.